Company: IPSC
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001104659-25-037419
Chunk: 32

Company: Century Therapeutics, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 32
---
 Cowan served as an Executive Scientific Advisor to us. Prior to this, Dr. Cowan founded and served as Chief Scientific Officer of Sana Biotechnology, Inc. from July 2018 until October 2019. Dr. Cowan co-founded and served as Head of Research at CRISPR Therapeutics, Inc. from May 2015 until May 2017. Dr. Cowan has served on the board of directors of Somite AI since September 2024. From May 2006 until May 2020, Dr. Cowan served as an associate professor at Harvard University and Harvard Medical School. Dr. Cowan received his B.A. and B.S., with honors, from the University of Kansas. He received his Ph.D. from the University of Texas Southwestern at Dallas and subsequently completed a Damon Runyon postdoctoral fellowship at Harvard University. Notice of Annual Meeting of Stockholders and 2025 Proxy Statement | 21

TABLE OF CONTENTS

| ​ | EXECUTIVE COMPENSATION | ​ |

This section discusses the material components of the executive compensation program for our named executive officers, or NEOs. In 2024, our NEOs were Brent Pfeiffenberger, Pharm.D., our President and Chief Executive Officer, Gregory Russotti, Ph.D., our Chief Technology and Manufacturing Officer and Adrienne Farid, Ph.D., our Chief Development Officer. SUMMARY COMPENSATION TABLE The following table sets forth information concerning the compensation of our 2024 NEOs during the fiscal years ended December 31, 2024 and December 31, 2023:

| ​ |    ​ | NAME AND                                                                                                                    
 PRINCIPAL                                                                                                                   
 POSITION                                                                                                                    | ​ |       ​ | YEAR | ​ | ​          | SALARY($) | ​ |         ​ | BONUS($)   | ​ |         ​ | STOCKAWARDS($) | ​ |       ​ | OPTIONAWARDS($)(1) | ​ |      ​ | NON-EQUITYINCENTIVEPLANCOMPENSATION($)(2) | ​ |         ​ | ALL OTHERCOMPENSATION($)(3) | ​ | ​ |  TOTAL($) | ​ | ​ |
| ​ |    ​ | Brent Pfeiffenberger, Pharm.D.,Presidentand Chief ExecutiveOfficer (4)                                                      | ​ |       ​ | 2024 | ​ | ​          |   625,000 | ​ |         ​ | 450,000(5) | ​ |         ​ |